TIM3, a human acute myeloid leukemia stem cell marker, does not enrich for leukemia-initiating stem cells in B-cell acute lymphoblastic leukemia

Clara Bueno; Alba Martínez; Paola Alejandra Romecin; Samanta Romina Zanetti; Ricky Tirtakusuma; Eulalia Genesca; Mireia Camós; Manuel Ramírez-Orellana; Eduardo Anguita; Paola Ballerini; Franco Locatelli; José Luis Fuster; Pablo Menéndez

doi:10.3324/haematol.2022.282394

TIM3, a human acute myeloid leukemia stem cell marker, does not enrich for leukemia-initiating stem cells in B-cell acute lymphoblastic leukemia

Haematologica. 2023 Aug 1;108(8):2229-2233. doi: 10.3324/haematol.2022.282394.

Affiliations

¹ Josep Carreras Leukemia Research Institute, Barcelona, Spain; Red Española de Terapias Avanzadas (TERAV)-Instituto de Salud Carlos III (ISCIII) (RICORS, RD21/0017/0029), Madrid, Spain; CIBER-ONC, ISCIII, Barcelona. cbueno@carrerasresearch.org.
² Josep Carreras Leukemia Research Institute, Barcelona, Spain; Red Española de Terapias Avanzadas (TERAV)-Instituto de Salud Carlos III (ISCIII) (RICORS, RD21/0017/0029), Madrid.
³ Josep Carreras Leukemia Research Institute, Barcelona.
⁴ Newcastle University, Newcastle upon Tyne.
⁵ Hematology Laboratory, Hospital Sant Joan de Déu. Barcelona. Spain; Leukemia and other pediatric hemopathies. Developmental tumor biology group. Instiutut de Recerca Hospital Sant Joan de Déu. Barcelona.
⁶ Red Española de Terapias Avanzadas (TERAV)-Instituto de Salud Carlos III (ISCIII) (RICORS, RD21/0017/0029), Madrid, Spain; Oncohematología. Hospital Niño Jesús. Madrid.
⁷ Servicio de Hematología. Hospital Clínico San Carlos. IdISSC, Medicina UCM. Madrid.
⁸ Pediatric Hematology. Armand Trosseau Hospital. Paris.
⁹ Department of Hematology and Oncology. Ospedale Bambino Gesú. Rome.
¹⁰ Sección de Oncohematología Pediátrica, Hospital Clínico Universitario Virgen de la Arrixaca and Instituto Murciano de Investigación Biosanitaria (IMIB), El Palmar, Murcia.
¹¹ Josep Carreras Leukemia Research Institute, Barcelona, Spain; Red Española de Terapias Avanzadas (TERAV)-Instituto de Salud Carlos III (ISCIII) (RICORS, RD21/0017/0029), Madrid, Spain; CIBER-ONC, ISCIII, Barcelona, Spain; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain; Department of Biomedicine. School of Medicine, University of Barcelona, Barcelona. pmenendez@carrerasresearch.org.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Hepatitis A Virus Cellular Receptor 2
Humans
Leukemia, Myeloid, Acute*
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma* / diagnosis
Stem Cells

Substances

Hepatitis A Virus Cellular Receptor 2

Grants and funding

Funding: Competitive financial support for this work was obtained from Spanish Ministry of Economy and Competitiveness (PID2019-108160RB-I00) to PM and (PLE2021-007518) to CB, the Carlos III Health Institute (ISCIII/FEDER PI20/00822) to CB, ISCIII-RICORS within the Next Generation EU program (plan de recuperación, transformación y resiliencia) to PM and Asociación Española Contra el Cancer (AECC) (PRYGN211192BUEN) to CB. SRZ was supported by a Marie Sklodowska Curie Fellosip (GA795833).